Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | SEMS: surgery as first-line therapy for seminoma

Siamak Daneshmand, MD, Keck School of Medicine, Los Angeles, CA, outlines the findings of the Phase II SEMS trial (NCT02537548) investigating surgery as a first-line treatment in early metastatic seminoma. The trial enrolled 55 patients who underwent retroperitoneal lymph node dissection (RPLND). At a median follow-up of 24 months, the overall recurrence rate was 18%, with a median time to recurrence of 8 months. The two-year recurrence-free survival rate was 87% and overall survival was 100%. This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.